We have discovered the expression of CD56 on the intravascular trophoblasts in the maternal spiral artery at implantation sites, and we have also found the similar phenotypic switch of intravascular trophoblasts in the decidual vasculopathy in preeclampsia. Currently we have examined 124 placentas from the patients with preeclampsia and 84 placentas from patients with other pregnancy associated complications without preeclampsia. CD56 expression on the intravascular trophoblasts can be seen in classic decidual vasculopathy such as fibrinoid medial necrosis and acute atherosis. In addition, partial involvement of the decidual vessels with classic vasculopathy can also be identified by CD56 expression. The cellular components of the classic vasculopathy in preeclampsia showed immunoreactivity to cytokeratin and CD68, in addition to CD56 expression, indicating the fetal trophoblastic cell origin. The classic decidual vasculopathy including acute atherosis and fibrinoid medial necrosis can be unified and designated as CD56-related vasculopathy. The CD56 related vasculopathy is associated not only to preeclampsia but also to other pregnancy related complications, such as gestational diabetes, placental infarcts, intervillous thrombosis and other fetal distress syndromes. Our study defined a spectrum of decidual vasculopathy spanning from the classic preeclampsia to other complications important to pregnancy that can be highlighted by CD56 expression, pointing to different direction of pathogenesis of preeclampsia and other pregnancy associated complications.
Introduction
Decidual (Maternal) vasculopathy is commonly associated with pregnancy induced hypertension or preeclampsia. There are three types of decidual vasculopathy that are clinically recognized, namely acute atherosis, fibrinoid medial necrosis and mural arterial hypertrophy (1). These types of vasculopathy are present in approximately 20-50% placentas from preeclampsia (1, 2). Two separate issues are commonly seen. On the one hand, no specific morphological features of decidual vessels are identified in the remaining 50-80% preeclamptic placentas with clinical manifestations (3, 4); on the other, there are morphological features of vasculopathy in normotensive patients with other pregnancy associated complications such as gestational diabetes, intervillous thrombosis, placenta infarcts, fetal meconium passage and aspiration, and occasionally normal term pregnancy without identifiable complications. How the vasculopathy occurs in preeclampsia and how to bridge these gaps in understanding the disease process remain poorly understood. Traditionally acute atherosis is characterized by the presence of foamy macrophages (cholesterol/lipid laden macrophages) within the intima of the maternal spiral artery in the similar fashion to aortic atherosclerosis, and these foamy macrophages are also phenotypically expressing CD68 (5-10). Fibrinoid medial necrosis is characterized by the fibrin-like eosinophilic hyalinized material within the maternal vascular walls immunohistochemically reactive to immunoglobulins and complements (5-10). Mural arterial hypertrophy is defined as the thickened decidual arteries similar to those in other tissue without trophoblastic remodeling and this type of vasculopathy is known to be more commonly associated with chronic hypertension (11, 12) . Through extensive laboratory and animal studies, preeclampsia is thought to be caused by poor cytotrophoblastic remodeling of spiral artery in early implantation and subsequently poor angiogenesis of placental vascular development (13-16). We have discovered that the trophoblastic remodeling of decidual spiral artery in early implantation is associated with phenotypic switch of trophoblasts to be immunohistochemically reactive to CD56, a maternal antigen likely from the natural killer cells within the decidua, and these trophoblasts with CD56 expression persist in vasculopathy in preeclamptic placenta but not in normal term pregnancy. We expanded our study to include more patients and other pregnancy complications associated with these types of vasculopathy. Our data showed acute atherosis and fibrinoid medial necrosis represent the spectrum of morphologic changes in the same category of vasculopathy. Both of which are CD56-related vasculopathy not only seen in preeclampsia but other complications in late pregnancy.
Material and methods
Prospectively 81 implantation sites (specimens including missed abortion, incomplete abortion, spontaneous abortion and abortions of medical reasons), 124 placentas with clinical indication of preeclampsia, and 84 placentas submitted for pathology examination for other pregnancy complications but no indication of preeclampsia for eight months prior to the study were collected and analyzed for decidual vascular changes with immunohistochemical staining for CD56, CD68, and cytokeratin (AE1/AE3). Pathologic changes, placental measurements and the associated clinical information and clinical diagnosis were collected at the time of clinical examination.
Paraffin embedded tissues from the routine surgical pathology specimens and the routine hematoxylin & eosin stained pathology slides were examined using light microscopy under the circumstance of normal routine pathology service. No special procedures are employed. Implantation sites, maternal vasculopathy such acute atherosis and fibrinoid medial necrosis in preeclampsia or unknown clinical conditions were identified in routine clinical service, and subsequently examined by immunostaining for CD56 expression.
Immunohistochemical staining procedures are performed on paraffin embedded tissues using Leica Biosystems Bond III automated immunostaining system following the manufacturing instruction. CD56 monoclonal antibody was purchased for clinical in vitro diagnostics from Agilent DAKO (mouse monoclonal antibody against human, Cat. # M730401-2) with appropriate dilutions and controls. AE1/AE3 and CD68 monoclonal antibodies were from Agilent DAKO under catalogue numbers M351501-2 and M081401-2 (Agilent DAKO, CA).
Results

Trophoblastic expression of CD56 in maternal spiral artery at implantation site:
We have reviewed 81 implantation sites from the routine pathology practice, and the decidual vessels were examined by light microscopy. Trophoblastic remodeling of the maternal spiral arteries are easily identified in the background of decidua with extravillous trophoblasts. The vascular walls within the implantation sites show various degrees of fibrinoid medial necrosis, a typical morphological feature of decidual vasculopathy in preeclampsia (Figure 1 ). The morphologic features of acute atherosis are also seen occasionally, but much less common than those of fibrinoid medial necrosis. Mural arterial hypertrophy of decidual vessels are commonly present in the implantation sites but its clinical significance is uncertain given the early stages of morphologic changes in the decidua and implantation. It remains possible that the spiral artery remodeling is yet to happen to these decidual vessels with mural hypertrophy in early implantation. There are scattered lymphocytes within the decidua tissue. Immunohistochemical staining for CD56 expression showed strong membrane/cytoplasmic staining signals only on the intravascular trophoblasts, but not on extravillous trophoblasts in the decidua (Figure 1 ). These intravascular trophoblasts are also reactive to AE1/AE3, indicating the fetal trophoblastic origin. These intravascular trophoblasts are also weakly reactive to CD68, a macrophage/monocyte/histiocyte marker. The lymphocytes within the decidua are positive for CD56 expression, consistent with the uterine natural killer (NK) cells as expected since CD56 is a defining marker for uterine NK cells. The extravillous trophoblasts within the decidua outside vessels are reactive to both AE1/AE3 and CD68, but not to CD56. Prospectively, immunostaining for CD56 expression was performed for 30 consecutive cases (implantation sites), and 100% of the intravascular (intraluminal) trophoblasts were stained positive. It is apparent that the intravascular (intraluminal) trophoblasts have undergone the phenotypic switch by acquisition of CD56 expression in implantation sites, and there is no need for immunostaining for additional cases for confirmation.
Trophoblastic expression of CD56 in decidual vasculopathy in preeclampsia:
Decidual vasculopathy including acute atherosis and fibrinoid medial necrosis is commonly present in the placentas from the patients with preeclampsia. Our previous survey indicated a relatively low percentage of placentas from the preeclamptic patients The clinical features of the 124 preeclamptic placentas are summarized in Table 1 based on the types of decidual vasculopathy and clinical/pathological complications.
There were totally 78 (63%) preeclamptic placentas with classic decidual vasculopathy and 36 (29%) preeclamptic placentas with no evidence of decidual vasculopathy. The placental weight and the gestational age distributions of these preeclamptic placentas with and without vasculopathy are shown in Figure 4 . The average (mean) weight for the preeclamptic placentas with classic vasculopathy is 438 grams, and for the preeclamptic placentas without vasculopathy 495 grams (p=0.02, unpaired student ttest) ( Table 1 ). The average preeclamptic placental weight with decidual vasculopathy is statistically lower than that without vasculopathy. The average gestational ages of the placentas with or without vasculopathy showed no significant difference.
Immunostains for CD56 was performed for 39 cases, and 37 cases showed demonstrable immunoreactivity to CD56 (95%). Two negative cases for CD56 immunostaining were due to the disappearance of the decidual vessels on the immunostaining slides and the deeper sections. The most common placental abnormality associated with classic decidual vasculopathy is infarcts (22%) followed by intervillous thrombosis (17%). Meconium stain of fetal membrane, fetal surface or amniotic fluid (15%), gestational diabetes (10%), and inflammatory conditions (9%) are also commonly associated with the presence of classic decidual vasculopathy.
Intrauterine growth restriction (IUGR), category 2 fetal heart tracing during labor, placental abruption (microscopic) and intrauterine fetal demise (IUFD) are present less frequently. There are 22% preeclamptic placentas with decidual vasculopathy showing no additional identifiable placental abnormalities.
The preeclamptic placentas without classic decidual vasculopathy (totally n=36) are also associated with other significant pathologic abnormalities such as infarcts (44%), inflammatory conditions (44%), intervillous thrombosis (17%), category 2 heart tracing during labor (11%), and meconium passage (6%). There were 11% preeclamptic placentas with no decidual vasculopathy showing no additional pathologic abnormalities.
Decidual vasculopathy without preeclampsia
There are clinical scenarios with complications in pregnancy such gestational diabetes, maternal thrombotic conditions, maternal fever, or abnormal fetal heart rate tracing during labor without co-existing diagnosis of preeclampsia. We have examined 84 consecutive placental cases with decidual vasculopathy and other pregnancy related complications, and these patients did not have diagnosis of preeclampsia or hypertension. The pathologic findings of these placentas are shown in Table 2 . The morphological features of decidual vasculopathy were identical to those seen in Figure   2 . The average (mean) placental weight from these non-preeclamptic patients (464 grams) shows no statistical difference from that of the preeclamptic patients (448 grams) (p=0.9, unpaired student t-test). The placental weight and the gestational age distributions of the 124 preeclamptic placentas and the 84 non-preeclamptic placentas are shown in Figure 5 . Immunostaining for CD56 expression were performed on 28 cases with identifiable decidual vasculopathy and all 28 cases were positive for CD56 reactivity (100%). The most common associated placental abnormalities from these non-preeclamptic placentas are similar to those seen in preeclamptic patients including infarcts (11%), thrombosis (17%), category 2 fetal heart tracing during labor (20%), meconium passages (23%), and inflammatory conditions such as chorioamnionitis or villitis (15%) (Table 2) with less frequent complications including IUGR (5%), abruption (4%) and IUFD (1%). There were 14% non-preeclamptic placentas with decidual vasculopathy showing no additional pathologic findings.
Discussion
Preeclampsia is a spectrum of clinical manifestations with various degrees of severities and the placental manifestations of preeclampsia are also diverse. Decidual vasculopathy is one of the defining features of preeclamptic placentas. In severe preeclampsia which represents approximately 5-20% of all preeclamptic patients, the placental villous tissue is hypoplastic with commonly associated decidual vasculopathy, placental infarcts and thrombosis (19). In these cases, the pathological changes of the placentas are easily identified on routine placental examination. Much commonly seen are mild forms of preeclampsia with borderline normal placentas and normal villous tissue development. In this mild form of preeclamptic cases, the placental pathological changes are harder to define, and decidual vasculopathy difficult to identify (17, 19).
CD56 immunostaining can be used as an adjunct marker for identifying the intravascular (intraluminal) trophoblasts, and decidual vasculopathy. The spectrum of decidual vasculopathy from typical acute atherosis, fibrinoid medial necrosis to partially involved decidual vessels by these changes can be defined by the immunostaining for CD56 expression. Practically these decidual vascular lesions in preeclampsia are probably better designated as "CD56 related vasculopathy", in comparison to another vascular lesion defined as "mural arterial hypertrophy". In addition, the term "CD56 related vasculopathy" appears to unify the spectrum of morphologic changes in decidual vasculopathy with implication of pathogenesis. Mural arterial hypertrophy is shown to be associated with significant pregnancy related complications (11). In light of CD56 expression of intravascular trophoblasts in classic decidual vasculopathy in this study, mural arterial hypertrophy seems to be a separate vascular entity with different pathogenic mechanism. Interestingly, CD56 expression is only found on intravascular trophoblasts and the scattered decidual NK cells. No other cell type in early implantation site or term placenta is found to be immunoreactive to CD56 expression.
Traditionally acute atherosis and fibrinoid medial necrosis are related morphologic changes characterized by the endothelial cell damage, immunoglobulins/complements deposits, fat/cholesterol deposits and macrophage phagocytosis (5-7, 10, 20) . Our current results demonstrated that these "macrophages" are phenotypically fetal trophoblasts in origin by immunostaining pattern for cytokeratin (AE1/AE3) expression.
These "macrophages" in the vessels are also immunoreactive to CD56 expression and weakly reactive to CD68 expression. Identification of these "foamy macrophages" as fetal trophoblasts with expression of CD56, a defining NK cells marker, points to an entirely different direction for pathogenesis of preeclampsia. CD56 expression is present in all implantation sites, and not present in the normal term placentas, indicating the disappearance of CD56 expression and/or intravascular trophoblasts is essential for normal pregnancy. Consequently, persistence of intravascular trophoblasts with CD56 expression at the late gestations is associated with pregnancy related complications. This is in contrast to the traditional view of the lack of spiral artery remodeling by the trophoblasts as a basis of preeclampsia (13-16). We have seen CD56 expression on intravascular trophoblasts in placentas of up to 24 week gestation from early premature delivery due to incompetent cervix or chorioamnionitis without evidence of decidual vascular insufficiency (maternal vascular malperfusion). Exactly how CD56 expression disappears in temporal fashion from early to late gestations requires further laboratory studies.
In light of immunostaining and knowledge of CD56 expression in decidual vasculopathy, there are still 29% preeclamptic placentas without identifiable decidual vasculopathy in the current study (Table 1) There is a soluble form of CD56 in the circulation (26, 28), and it will be interesting and useful to see if the levels of the soluble CD56 is associated with development of preeclampsia. .
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